Past and Present Research Support
CTSC grant from Case Western Reserve University. Electroconvulsive therapy in multiple system atrophy. 6/1/11 to 5/31/12. Thomas Chelimsky PI. $50k over 1 year.
Principle Investigator R01-DK083538 NIH NIDDK Interstitial Cystitis Elucidation of Psychophysiologic and Autonomic Characteristics (ICEPAC). 7/1/09 to 6/30/14. $3,734,188 over 5 years. Co-Investigators: Buffington CAT, Janata, J
Co-PI R13NS073226-01 (NINDS), $15,000 Primary Care Workshop in Autonomic Disorders and Syncope Marco Island, November 2010
Research Mentor, Brain-Heart Institute Award (5% effort); “Central Autonomic Regulation in Complex Regional Pain Syndrome” $150,000; 1/1/09 to 1/1/11. PI Chemali, K
Double-blind placebo-controlled trial of rasagiline as neuroprotective agent in multiple system atrophy. Teva Pharmaceuticals; Sid Gilman study director. 7/1/10 – Study termination.
Principle Investigator Fishbein Family IC Research Foundation (5% effort): "Familial Aggregation of Interstitial Cystitis with Other Functional Autonomic Disorders" $28,668; 10/1/07 to 9/30/08 Co-investigators: Buffington, T; Rackley, R.
Principle Investigator (40% effort) funded by Josiah Macy Jr. Foundation, NY, “A controlled study of an interdisciplinary pain management approach led by primary care physicians” The 4PCP trial (Primary Practice Program for Patients with Chronic Pain). $983,076. 7/1/04 to 6/30/09.
Double-blind placebo-controlled trial of Droxidopa (L-3,4-DOPS) in orthostatic hypotension. Chelsea Pharmaceuticals study investigator (5% effort). 3/1/08 to study termination. H Kaufman study director.
Site Principle Investigator (approx 5% effort), NIH multi-center study, P01 NS44233 “The pathogenesis and diagnosis of multiple system atrophy”; Project P.I. Cliff Shults, MD (UCSD Dept of Neuroscience). 7/1/03 to 6/30/06.
Shire 404 study investigator (approx 3% effort): “A Multi-Center, Double-Blind, Randomized, Placebo-Controlled Crossover Study to Assess the Clinical Benefit of Midodrine Hydrochloride in Subjects with Moderate to Severe Neurogenic Orthostatic Hypotension” (Protocol SPD426.404). 10/1/04 to 4/30/05.
Shire 401 study investigator (approx 5% effort): “A Multi-Center, Double-Blind, Randomized, Placebo-Controlled Crossover Study to Assess the Clinical Benefit of Midodrine Hydrochloride in Subjects with Neurogenic Orthostatic Hypotension” (Protocol 20,762-401). 10/1/03 to 1/15/05.
Roberts Pharmaceutical Corporation (approx 5% effort): Phase 3 Study of Midodrine Hydrochloride in Subjects with Neurogenic Orthostatic Hypotension. 7/1/94 to 6/1/95.
Case Research Development Grant (RIG - $5000): Autonomic Changes in Patients with Arthritic Limb Pain. 7/1/93 to 7/1/94.